Drug intelligence / Profile preview

camrelizumab + gemcitabine + nab-paclitaxel

Development stage: Unknown
Lead developer: Hengrui Pharmaceutical
Modality: Nanoparticles → Drug Delivery Systems, Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

Camrelizumab + gemcitabine + nab-paclitaxel is a combination chemo-immunotherapy regimen being evaluated for the treatment of metastatic pancreatic ductal adenocarcinoma (PDAC). The combination consists of camrelizumab (SHR-1210), a humanized IgG4 monoclonal antibody that targets the programmed death-1 (PD-1) receptor to enhance anti-tumor immune responses; gemcitabine, a nucleoside analog that interferes with DNA synthesis; and nab-paclitaxel (albumin-bound paclitaxel), a microtubule inhibitor that promotes tubulin polymerization and stabilizes microtubules. This triplet therapy is currently being investigated in a Phase I clinical trial at RenJi Hospital as a first-line treatment strategy, aiming to improve clinical outcomes in patients with advanced pancreatic cancer by combining immune checkpoint blockade with standard cytotoxic chemotherapy.

Brand names: AbraxaneGemzar
Other names: SHR-1210 + gemcitabine + nab-paclitaxelCamrelizumab + gemcitabine + albumin-bound paclitaxel

Targets

PDCD1 (Programmed cell death protein 1 receptor)TUBB (Tubulin (alpha and beta subunits))DNA

Beyond the preview

Go deeper on camrelizumab + gemcitabine + nab-paclitaxel.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on camrelizumab + gemcitabine + nab-paclitaxel.

Explore the full profile